NCT00731302View on ClinicalTrials.gov

Aspirin Resistance in Systemic Lupus Erythematosus (SLE)

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

aspirin and meloxicam

aspirin 81 mg daily then aspirin 81 mg plus meloxicam 7.5 mg daily

Trial Locations (2)

37232

Vanderbilt University Medical School, Nashville

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Vanderbilt University

OTHER

NCT00731302 - Aspirin Resistance in Systemic Lupus Erythematosus (SLE) | Biotech Hunter | Biotech Hunter